MannKind Corp. (Nasdaq: MNKD) will host a conference call to discuss the company's commercialization strategy for the inhalable insulin Afrezza. The stock price soared 30 cents to close at $1.52.
MannKind to outline commercialization strategy
April 11, 2016 at 17:22 PM EDT
